Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cisplatin/Paclitaxel vs Cisplatin/Gemcitabine in Advanced Cervical Cancer
NCT00057928Phase 3Withdrawn
- Sponsor
- SWOG Cancer Research Network
- Start
- Apr 2003
- Primary completion
- Jul 2003
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial in Cervical Cancer (CC) comparing Cisplatin + Paclitaxel with Cisplatin + Gemcitabine (2 arms). Primary endpoints: Overall Survival at 5 years, Progression-Free Survival at 5 years and 2 more. Planned start Apr 2003; status: withdrawn.
02
Drugs
paclitaxelgemcitabine
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT00057928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00057928.